Hyaluronic Acid-doxorubicin Nanoparticles for Targeted Treatment of Colorectal Cancer

Overview

Journal Bioeng Transl Med

Date 2021 Feb 3

PMID 33532580

Citations 12

Authors

Daniel C Pan

Vinu Krishnan

Alyssa K Salinas

Jayoung Kim

Tao Sun

Sagi Ravid

Kevin Peng

Debra Wu

Md Nurunnabi

Jeffery A Nelson

Zachary Niziolek

Junling Guo

Samir Mitragotri

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer, common in both men and women, occurs when tumors form in the linings of the colon. Common treatments of colorectal cancer include surgery, chemotherapy, and radiation therapy; however, many colorectal cancer treatments often damage healthy tissues and cells, inducing severe side effects. Conventional chemotherapeutic agents such as doxorubicin (Dox) can be potentially used for the treatment of colorectal cancer; however, they suffer from limited targeting and lack of selectivity. Here, we report that doxorubicin complexed to hyaluronic acid (HA) (HA-Dox) exhibits an unusual behavior of high accumulation in the intestines for at least 24 hr when injected intravenously. Intravenous administrations of HA-Dox effectively preserved the mucosal epithelial intestinal integrity in a chemical induced colon cancer model in mice. Moreover, treatment with HA-Dox decreased the expression of intestinal apoptotic and inflammatory markers. The results suggest that HA-Dox could effectively inhibit the development of colorectal cancer in a safe manner, which potentially be used a promising therapeutic option.

Citing Articles

Targeted Delivery of Gemcitabine for Precision Therapy of Cholangiocarcinoma Using Hyaluronic Acid-Modified Metal-Organic Framework Nanoparticles.

Long C, Peng H, Yang W, Wang M, Luo B, Hao J ACS Omega. 2024; 9(10):11998-12005.

PMID: 38496964 PMC: 10938583. DOI: 10.1021/acsomega.3c09751.

Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade.

Zhang B, Li N, Gao J, Zhao Y, Jiang J, Xie S J Exp Clin Cancer Res. 2024; 43(1):51.

PMID: 38373953 PMC: 10875809. DOI: 10.1186/s13046-024-02974-4.

Glycosaminoglycans' Ability to Promote Wound Healing: From Native Living Macromolecules to Artificial Biomaterials.

Yang P, Lu Y, Gou W, Qin Y, Tan J, Luo G Adv Sci (Weinh). 2023; 11(9):e2305918.

PMID: 38072674 PMC: 10916610. DOI: 10.1002/advs.202305918.

Synergistic ferroptosis-starvation therapy for bladder cancer based on hyaluronic acid modified metal-organic frameworks.

Wang Y, Xie K, Chen W, Fang Y, Mo Q, Zhang H Bioeng Transl Med. 2023; 8(3):e10515.

PMID: 37206228 PMC: 10189452. DOI: 10.1002/btm2.10515.

Targeting pathophysiological changes using biomaterials-based drug delivery systems: A key to managing inflammatory bowel disease.

Mohajeri S, Moayedi S, Mohajeri S, Yadegar A, Haririan I Front Pharmacol. 2022; 13:1045575.

PMID: 36438794 PMC: 9685402. DOI: 10.3389/fphar.2022.1045575.

References

Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum Y . Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001; 19(5):1501-18. DOI: 10.1200/JCO.2001.19.5.1501. View

Rothenberg M . Efficacy of oxaliplatin in the treatment of colorectal cancer. Oncology (Williston Park). 2001; 14(12 Suppl 11):9-14. View

Hameed H, Cassidy J . Use of capecitabine in management of early colon cancer. Cancer Manag Res. 2011; 3:295-9. PMC: 3173019. DOI: 10.2147/CMR.S12704. View

Chambers E, Mitragotri S . Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation. Exp Biol Med (Maywood). 2007; 232(7):958-66. View

Afzal S, Jensen S, Vainer B, Vogel U, Matsen J, Sorensen J . MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol. 2009; 20(10):1660-6. DOI: 10.1093/annonc/mdp046. View

Kim G, Sargent D, Mahoney M, Rowland Jr K, Philip P, Mitchell E . Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009; 27(17):2848-54. PMC: 2698019. DOI: 10.1200/JCO.2008.20.4552. View

Verdaguer H, Tabernero J, Macarulla T . Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2016; 8(3):230-42. PMC: 4872251. DOI: 10.1177/1758834016635888. View

Brown J, DuBois R . COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005; 23(12):2840-55. DOI: 10.1200/JCO.2005.09.051. View

Teufel A, Steinmann S, Siebler J, Zanke C, Hohl H, Adami B . Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer. 2004; 4:38. PMC: 497044. DOI: 10.1186/1471-2407-4-38. View

10.

Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K . Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci. 2019; 110(11):3565-3572. PMC: 6825011. DOI: 10.1111/cas.14198. View

11.

Syed Y, McKeage K . Aflibercept: A Review in Metastatic Colorectal Cancer. Drugs. 2015; 75(12):1435-45. DOI: 10.1007/s40265-015-0444-4. View

12.

Andreyev H . A physiological approach to modernize the management of cancer chemotherapy-induced gastrointestinal toxicity. Curr Opin Support Palliat Care. 2009; 4(1):19-25. DOI: 10.1097/SPC.0b013e32833575cc. View

13.

Mitchell E . Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clin Colorectal Cancer. 2012; 12(2):73-85. DOI: 10.1016/j.clcc.2012.08.001. View

14.

Viswanathan C, Bhosale P, Ganeshan D, Truong M, Silverman P, Balachandran A . Imaging of complications of oncological therapy in the gastrointestinal system. Cancer Imaging. 2012; 12:163-72. PMC: 3362867. DOI: 10.1102/1470-7330.2012.0014. View

15.

Zlobec I, Baker K, Terracciano L, Lugli A . RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res. 2008; 14(12):3798-806. DOI: 10.1158/1078-0432.CCR-07-5103. View

16.

Romano M, De Francesco F, Zarantonello L, Ruffolo C, Ferraro G, Zanus G . From Inflammation to Cancer in Inflammatory Bowel Disease: Molecular Perspectives. Anticancer Res. 2016; 36(4):1447-60. View

17.

Snyder M, Bottiglieri S, Almhanna K . Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer. Rev Recent Clin Trials. 2018; 13(2):139-149. DOI: 10.2174/1574887113666180328104109. View

18.

Lugli A, Zlobec I, Gunthert U, Minoo P, Baker K, Tornillo L . Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Mod Pathol. 2006; 19(10):1302-9. DOI: 10.1038/modpathol.3800648. View

19.

Lee C, Ryan E, Doherty G . Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol. 2014; 20(14):3751-61. PMC: 3983434. DOI: 10.3748/wjg.v20.i14.3751. View

20.

Alphandery E, Grand-Dewyse P, Lefevre R, Mandawala C, Durand-Dubief M . Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. Expert Rev Anticancer Ther. 2015; 15(10):1233-55. DOI: 10.1586/14737140.2015.1086647. View